The Diagnostic Role of Thyroid Nodules

An Indeterminate FNA Finding

Thyroid nodules are increasingly prevalent. Although 85% to 95% of thyroid nodules are benign,6,7 thyroid cancer is the most common endocrine cancer and ranks as the ninth most common cancer in the United States.2

Palpable thyroid nodules occur in 5% to 7% of the adult population, but only 5% to 15% of those are diagnosed as thyroid cancer. Fine needle aspiration (FNA) is currently the standard preoperative diagnostic procedure used to evaluate thyroid nodules for cancer risk.

Cytologic examination results are often indeterminate

Up to 35% of FNA biopsy results are indeterminate.3

Among patients with cytologically indeterminate biopsies, the risk of malignancy can vary widely between institutions.3,8

~66% of nodules obtained from diagnostic surgery (hemithyroidectomy) are benign.9

Coming Soon: Molecular Testing-Based Cytology Smear Slides

Limitations and Disclaimers:

The ThyraMIR™ microRNA Classifier and the ThyGenX® Oncogene Panel each consist of markers strongly associated with thyroid cancer and whose detection in preoperative thyroid nodule aspirations have been shown to be highly predictive for thyroid cancer. These tests are intended to aid in the diagnosis of thyroid nodules with indeterminate cytology; positive or negative test results should be interpreted in conjunction with all other available clinical data. These tests were developed and performance characteristics determined by Interpace Diagnostics. They have not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing used for clinical purposes. These tests are used for clinical purposes. Tests should not be regarded as investigational or for research. Final diagnosis and optimal patient management are the responsibility of the referring physician or health care provider.